MOTS-c and SS-31
Do MOTS-c and SS-31 work together as a mitochondrial stack, and is there any human evidence for either?
Reviewed by the amino101 editorial team. .
Also searched as mitochondrial peptide stack, MOTS-c elamipretide stack, SS-31 MOTS-c combo.
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that acts as a metabolic signal, improving insulin sensitivity and exercise capacity in mice. People use it for fat loss, endurance, and metabolic aging.
SS-31 is a four-amino-acid peptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, stabilizing energy production. As elamipretide it has been through multiple human trials, most notably for the rare mitochondrial disease Barth syndrome.
MOTS-c and SS-31 are stacked because they act on mitochondria from two directions. MOTS-c is a 16 amino acid peptide encoded in mitochondrial DNA that signals through AMPK, improving glucose uptake, fat oxidation and mitochondrial biogenesis in muscle. SS-31 is a four amino acid synthetic peptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, stabilizing the electron transport chain so it leaks fewer electrons. The theory is that one drives metabolic adaptation while the other protects the machinery it acts on. The evidence is lopsided. MOTS-c is almost entirely mouse data; native MOTS-c has never been through a human trial, and only its analog CB4211 has phase 1 results. SS-31 is elamipretide, a clinical-stage drug with a long trial record and an FDA accelerated approval for the rare disease Barth syndrome in 2025, though its largest trial in general mitochondrial myopathy was negative.
Nobody has studied the two together, and the community dosage of SS-31, 5 to 10 mg daily, is a fraction of the 40 mg clinical dose. This page covers what each compound has actually shown, how people dose them together, and why most healthy users notice little that is measurable. The MOTS-c vs SS-31 page compares them head to head. Both are unapproved for this use, MOTS-c is WADA prohibited, and this is educational background only.
Why people combine MOTS-c and SS-31
MOTS-c inhibits a folate cycle enzyme, raising AICAR and activating AMPK, which resembles the muscle response to exercise. SS-31 does not scavenge radicals; it binds cardiolipin and physically restores cristae structure so ATP output improves and reactive oxygen species fall. One tells muscle to adapt, the other keeps the mitochondria able to. The complementarity is real in theory and untested in practice.
MOTS-c roughly doubled running capacity in old mice in a 2021 study. A single dose of SS-31 improved muscle energetics and exercise tolerance in aged mice within an hour. Those two findings are why the stack is sold for endurance and aging; neither has been replicated in healthy humans.
Elamipretide has been through trials in heart failure, mitochondrial myopathy, macular degeneration and Barth syndrome. Results were mixed, with a negative phase 3 in mitochondrial myopathy and a positive open-label extension in Barth syndrome that supported accelerated approval. Research grade SS-31 is not that product, but at least the molecule has a safety record at 40 mg daily.
Neither peptide is an exercise substitute, and the MOTS-c mouse doses per kilogram are far above what people use. The stack adds nothing for someone who is not training, and the SS-31 compound page is blunt that community doses may be placebo. Adding a third mitochondrial compound such as NAD+ does not fix the lack of human data; it adds another injection with its own flush.
MOTS-c and SS-31 dosage and protocol
What appears in research and community protocols for each compound in the stack. Not a prescription.
| Peptide | Dosage | Frequency | Timing and route |
|---|---|---|---|
| MOTS-c | 5 to 10 mg | two to three times per week | subcutaneous in the abdomen or thigh, morning or 30 to 60 minutes before training, often fasted |
| SS-31 | 5 to 10 mg | once daily | subcutaneous in the abdomen or thigh, morning, rotating sites daily because injection reactions are common |
Both are run 4 to 8 weeks then paused, MOTS-c for about 4 weeks and SS-31 for 2 to 4 weeks. Clinical elamipretide use is continuous, so the break is caution and cost rather than evidence. Some people front-load MOTS-c at three doses a week for two weeks and drop to two. The SS-31 page suggests stopping at 8 weeks if nothing measurable has changed.
- •MOTS-c dosing on training days is the most common schedule, on the theory that it works through the same AMPK pathway exercise activates.
- •Anyone on glucose-lowering drugs usually eats around the MOTS-c injection, since transient glucose dips are reported.
- •SS-31 injection site redness and lumps build up with repeated use of one spot. Rotate daily, and keep the MOTS-c injection out of the same area so reactions can be traced.
- •Tracking something, such as resting heart rate, a timed run or fasting glucose, is the only way to tell whether 8 weeks did anything.
Work out syringe units for any of these in the dosage calculator.
Can you mix MOTS-c and SS-31 in one syringe?
Both are reconstituted with bacteriostatic water and have no known chemical conflict, and SS-31 is more stable than most peptides because of its unnatural residues. People do draw them into one syringe on days both are due, though no stability data exists for the mixture. The practical argument against mixing is schedule and site: SS-31 is daily and MOTS-c is two or three times a week, and SS-31's injection reactions are easier to attribute when it has its own site. Vendors sell MOTS-c and SS-31 blends, usually 10 mg of each per vial, which force a 1 to 1 ratio on every dose; the injection sites article covers rotation.
What to expect, week by week
- Week 1 to 2
Injection site redness from both, itching or small lumps from SS-31, possibly a short spell of fatigue or flushing after MOTS-c. Some report better energy right away, which may be placebo.
- Week 2 to 4
Reports of easier cardio and better recovery are the most common claim. Nothing on the scale. In trial populations any SS-31 effect took months to show on objective measures.
- Week 4 to 8
Modest body composition change if any, mostly in people who are also training and dieting. Most healthy users notice little that is measurable.
- Beyond week 8
If nothing has changed, both compound pages say stop. Continuing without a marker that moved is spending money on hope.
Side effects and cautions
- ▲Injection site redness, itching, swelling or small lumps, especially from SS-31
- ▲Transient fatigue or flushing after a MOTS-c dose
- ▲Temporary drops in blood glucose from MOTS-c
- ▲Headache, reported with both
- ▲Dizziness from SS-31
- ▲Mild nausea from either
- ▲Fatigue in some SS-31 users, the opposite of what they expected
- ■Anyone on insulin, metformin or other glucose-lowering drugs. MOTS-c improves glucose uptake, and both it and metformin act through AMPK, so readings need watching rather than assuming it is fine.
- ■Tested athletes. MOTS-c is WADA prohibited and SS-31 falls under the non-approved substance catch-all.
- ■Anyone with a diagnosed mitochondrial disease. That is a specialist's territory, and the one indication where elamipretide is approved comes with clinical monitoring at a dose four to eight times what people use at home.
- ■Anyone expecting it to replace training. The whole rationale is exercise mimicry, and neither compound page thinks it does much in someone who is not also exercising.
This stack is for someone who already trains hard, is curious about mitochondrial biology, and can afford an experiment that may well show nothing. SS-31 is the half with human data and the half worth running alone first; its injection reactions are the main cost and its benefit in healthy people is unproven. MOTS-c is the more speculative half, with striking mouse data and nothing in humans, and the training day schedule at least gives it a plausible context. Running both from the start means paying for two compounds and learning nothing about either. Someone who wants a metabolic nudge during a diet is better served by the weight loss pages and by lifting. Someone with a real mitochondrial condition needs a specialist, not a vendor. Both are unapproved for this use, MOTS-c is WADA prohibited, and this page is educational background rather than a protocol.
MOTS-c and SS-31: frequently asked
Is SS-31 the same as elamipretide?
Same molecule. Elamipretide is the drug name used in trials and for the approved product Forzinity. SS-31 is the original research code, and the vials sold by peptide vendors are chemically meant to match but are not manufactured or tested to pharmaceutical standards.
What is the MOTS-c and SS-31 dosage?
Community protocols use 5 to 10 mg of MOTS-c two or three times a week and 5 to 10 mg of SS-31 once daily. The clinical elamipretide dose is 40 mg daily, and the mouse MOTS-c doses scale to far more than anyone injects, so neither community number has human efficacy data behind it. The peptide dosage chart lists both.
Does MOTS-c actually improve endurance?
In mice, yes: old mice roughly doubled their running time. Exercise also raises MOTS-c in human muscle and plasma. Whether an injected dose gives a person any meaningful fraction of what training does has never been tested.
Should you add NAD+ to the MOTS-c and SS-31 stack?
People do, on the logic that NAD+ feeds the electron transport chain SS-31 stabilizes. It is a third compound with no combined data and its own injection flush. The NAD+ and glutathione page covers that pairing separately.
Is MOTS-c or SS-31 better on its own?
SS-31 has a human safety record and a narrow approval; MOTS-c has better rodent endurance data and none in humans. For someone who wants the compound with trial backing, SS-31. For an exercise-focused experiment, MOTS-c. See MOTS-c vs SS-31.
Can MOTS-c and SS-31 be taken with a GLP-1 drug?
Both compound pages list semaglutide as compatible with no known conflict; people add them during weight loss hoping to protect exercise capacity. There is no combined data, and the glucose dip from MOTS-c is worth watching when eating less.
Related reading
Cellular energy and antioxidant support
Weight loss while limiting muscle loss
Two mitochondrial peptides, usually run together. What does each one actually do?
Two injectables sold alongside peptides that are not really peptides. What does each one do?
Guide
Guide
Guide
News
Sources
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021
- Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology, 2023
- First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 2014